Compounds > indazoles
Page last updated: 2024-08-21

indazoles and Macular Degeneration

indazoles has been researched along with Macular Degeneration in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19901 (20.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Haniuda, H; Horita, S; Kagawa, Y; Katagiri, M; Nakamura, H; Nakazato, T; Watanabe, M1
Danis, R; Johnson, MW; Kim, RY; McLaughlin, MM; Staurenghi, G; Tolentino, M; Xu, CF; Ye, L1
Eibl-Lindner, K; Liegl, R; Priglinger, C; Priglinger, S; Siedlecki, J; Wertheimer, C; Wolf, A1
Eichler, W; King, AG; Lange, J; Niemeyer, M; Nishiwaki, A; Wiedemann, P; Yafai, Y; Yang, XM; Yasukawa, T1
Elliott, DB; Gilchrist, J; Hurst, M; Pickwell, LD; Sheridan, M; Weatherill, J; Whitaker, D1

Trials

1 trial(s) available for indazoles and Macular Degeneration

ArticleYear
Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration.
    The British journal of ophthalmology, 2014, Volume: 98, Issue:2

    Topics: Angiogenesis Inhibitors; Choroidal Neovascularization; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Indazoles; Macular Degeneration; Male; Middle Aged; Ophthalmic Solutions; Prospective Studies; Pyrimidines; Sulfonamides; Treatment Outcome; Visual Acuity

2014

Other Studies

4 other study(ies) available for indazoles and Macular Degeneration

ArticleYear
Species differences in ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib eye-drops among rats, rabbits and monkeys.
    Pharmacology research & perspectives, 2019, Volume: 7, Issue:6

    Topics: Angiogenesis Inhibitors; Animals; Choroidal Neovascularization; Crystallization; Disease Models, Animal; Drug Evaluation, Preclinical; Eye; Female; Humans; Indazoles; Macaca fascicularis; Macular Degeneration; Male; Nanoparticles; Ophthalmic Solutions; Particle Size; Phenylurea Compounds; Pyridines; Pyrimidines; Rabbits; Rats; Receptors, Vascular Endothelial Growth Factor; Species Specificity; Sulfonamides; Vascular Endothelial Growth Factor A

2019
Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2017, Volume: 255, Issue:5

    Topics: Axitinib; Cell Proliferation; Cell Survival; Cells, Cultured; Choroidal Neovascularization; Endothelium, Vascular; Humans; Imidazoles; Indazoles; Macular Degeneration; Pericytes; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Signal Transduction; Vascular Endothelial Growth Factor A

2017
Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats.
    European journal of pharmacology, 2011, Volume: 666, Issue:1-3

    Topics: Administration, Topical; Angiogenesis Inhibitors; Animals; Cell Movement; Choroid; Down-Regulation; Endothelial Cells; Humans; Indazoles; Intracellular Space; Macular Degeneration; Male; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrimidines; Rats; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sulfonamides; Vascular Endothelial Growth Factor A

2011
The subjective assessment of cataract.
    Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists), 1989, Volume: 9, Issue:1

    Topics: Aged; Cataract; Contrast Sensitivity; Humans; Indazoles; Macular Degeneration; Refractive Errors; Scattering, Radiation; Sensory Thresholds; Visual Acuity

1989